Atopic Dermatitis and Allergic Contact Dermatitis

[1]  M. Shaker,et al.  Frequent Versus Infrequent Bathing in Pediatric Atopic Dermatitis: A Randomized Clinical Trial , 2020, Pediatrics.

[2]  A. Schnuch,et al.  Genetics and Individual Predispositions in Contact Dermatitis , 2020, Contact Dermatitis.

[3]  Lisa J. Martin,et al.  Disease-associated KIF3A variants alter gene methylation and expression impacting skin barrier and atopic dermatitis risk , 2020, Nature Communications.

[4]  M. Kawashima,et al.  Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. , 2020, The New England journal of medicine.

[5]  John D. Davis,et al.  Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. , 2020, Journal of the American Academy of Dermatology.

[6]  J. Werth,et al.  Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1) , 2020, American Journal of Clinical Dermatology.

[7]  D. Bernstein,et al.  A Hands-on Approach to Contact Dermatitis and Patch Testing. , 2020, The journal of allergy and clinical immunology. In practice.

[8]  L. Fonacier,et al.  Allergic Contact Dermatitis. , 2020, The Medical clinics of North America.

[9]  G. Lack,et al.  Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial. , 2019, JAMA pediatrics.

[10]  John D. Davis,et al.  Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis , 2019, JAMA dermatology.

[11]  D. Margolis,et al.  Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. , 2019, The Journal of investigative dermatology.

[12]  H. Kong,et al.  Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions” , 2019, The Journal of allergy and clinical immunology.

[13]  E. Guttman‐Yassky,et al.  The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment , 2019, Clinical Reviews in Allergy & Immunology.

[14]  M. Boguniewicz,et al.  Strategies for Successful Management of Severe Atopic Dermatitis. , 2019, The journal of allergy and clinical immunology. In practice.

[15]  R. Robison,et al.  Controversies in Allergy: Food Testing and Dietary Avoidance in Atopic Dermatitis. , 2019, The journal of allergy and clinical immunology. In practice.

[16]  M. Boguniewicz,et al.  The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition , 2018, Experimental dermatology.

[17]  M. Zirwas.  Contact Dermatitis to Cosmetics , 2018, Clinical Reviews in Allergy & Immunology.

[18]  E. Warshaw,et al.  North American Contact Dermatitis Group Patch Test Results: 2015–2016 , 2018, Dermatitis : contact, atopic, occupational, drug.

[19]  J. Thyssen,et al.  Prevalence of contact allergy in the general population: A systematic review and meta‐analysis , 2018, Contact dermatitis.

[20]  L. Fonacier,et al.  Irritant Contact Dermatitis , 2018, Clinical Reviews in Allergy & Immunology.

[21]  A. Atwater,et al.  Positive Patch Test Reaction in a Patient Taking Dupilumab. , 2018, Dermatitis : contact, atopic, occupational, drug.

[22]  M. Boguniewicz.  Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines. , 2017, The journal of allergy and clinical immunology. In practice.

[23]  J. Silverberg,et al.  Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  V. Arrandale,et al.  Preventing Occupational Skin Disease: A Review of Training Programs , 2017, Dermatitis : contact, atopic, occupational, drug.

[25]  D. Margolis,et al.  The burden of skin disease in the United States , 2017, Journal of the American Academy of Dermatology.

[26]  Yu-Chen Huang,et al.  Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. , 2016, The Journal of allergy and clinical immunology.

[27]  M. Lebwohl,et al.  Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. , 2016, Journal of the American Academy of Dermatology.

[28]  H. Williams,et al.  Specific allergen immunotherapy for the treatment of atopic eczema. , 2016, The Cochrane database of systematic reviews.

[29]  Manuel A. R. Ferreira,et al.  Multi-ethnic genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis , 2015, Nature Genetics.

[30]  L. Fonacier.  A Practical Guide to Patch Testing. , 2015, The journal of allergy and clinical immunology. In practice.

[31]  A. Paller,et al.  A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. , 2015, Journal of the American Academy of Dermatology.

[32]  J. Krueger,et al.  The translational revolution and use of biologics in patients with inflammatory skin diseases. , 2015, The Journal of allergy and clinical immunology.

[33]  James T. Elder,et al.  Genome-wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms , 2015, American journal of human genetics.

[34]  G. Yancopoulos,et al.  Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[35]  C. Camargo,et al.  Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. , 2014, The Journal of allergy and clinical immunology.

[36]  P. Elias,et al.  Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[37]  D. Leung,et al.  Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. , 2014, The Journal of allergy and clinical immunology.

[38]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. , 2014, Journal of the American Academy of Dermatology.

[39]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[40]  Yusuke Nakamura,et al.  Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population , 2012, Nature Genetics.

[41]  C. la Vecchia,et al.  Probiotics Supplementation During Pregnancy or Infancy for the Prevention of Atopic Dermatitis: A Meta-analysis , 2012, Epidemiology.

[42]  T. Beaty,et al.  Genetic Variants in Interferon Regulatory Factor 2 (IRF2) are Associated with Atopic Dermatitis and Eczema Herpeticum , 2011, The Journal of investigative dermatology.

[43]  A. Irvine,et al.  Filaggrin mutations associated with skin and allergic diseases. , 2011, The New England journal of medicine.

[44]  Takami Yoshida,et al.  Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis. , 2011, The Journal of allergy and clinical immunology.

[45]  A. Bowcock,et al.  Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. , 2011, The Journal of allergy and clinical immunology.

[46]  M. Boguniewicz,et al.  Atopic dermatitis: a disease of altered skin barrier and immune dysregulation , 2011, Immunological reviews.

[47]  M. D. de Bruin‐Weller,et al.  Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. , 2011, Journal of the American Academy of Dermatology.

[48]  A. Bowcock,et al.  Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. , 2011, The Journal of allergy and clinical immunology.

[49]  P. Spuls,et al.  Off-label use of azathioprine in dermatology: a systematic review. , 2011, Archives of dermatology.

[50]  K. Barnes,et al.  Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response. , 2011, The Journal of allergy and clinical immunology.

[51]  T. Beaty,et al.  Tight junction defects in patients with atopic dermatitis. , 2011, The Journal of allergy and clinical immunology.

[52]  Jae-Won Oh,et al.  Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis , 2011, Allergy, asthma & immunology research.

[53]  J. Schmitt,et al.  Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta‐analysis of randomized controlled trials , 2011, The British journal of dermatology.

[54]  G. Stingl,et al.  Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo‐controlled and double blind pilot study , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[55]  M. Rademaker,et al.  Narrowband UVB phototherapy in children: A New Zealand experience , 2010, The Australasian journal of dermatology.

[56]  H. Ogawa,et al.  Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. , 2010, The Journal of allergy and clinical immunology.

[57]  N. Nicol,et al.  The role of the nurse educator in managing atopic dermatitis. , 2010, Immunology and allergy clinics of North America.

[58]  L. Bielory,et al.  Atopic dermatitis and keratoconjunctivitis. , 2010, Immunology and allergy clinics of North America.

[59]  J. Na,et al.  Recalcitrant atopic dermatitis treated with omalizumab. , 2010, Annals of dermatology.

[60]  M. Klinnert,et al.  Addressing psychosocial aspects of atopic dermatitis. , 2010, Immunology and allergy clinics of North America.

[61]  P. Eigenmann,et al.  Allergic triggers in atopic dermatitis. , 2010, Immunology and allergy clinics of North America.

[62]  T. Beaty,et al.  Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. , 2010, The Journal of allergy and clinical immunology.

[63]  D. Amrol.  Anti-Immunoglobulin E in the Treatment of Refractory Atopic Dermatitis , 2010, Southern medical journal.

[64]  S. Ziegler,et al.  Sensing the outside world: TSLP regulates barrier immunity , 2010, Nature Immunology.

[65]  H. Kittler,et al.  5‐Methoxypsoralen plus ultraviolet (UV) A is superior to medium‐dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial , 2010, The British journal of dermatology.

[66]  A. Romano,et al.  Omalizumab efficacy in a girl with atopic eczema , 2010, Allergy.

[67]  Donald Y M Leung,et al.  Allergic skin diseases. , 2010, The Journal of allergy and clinical immunology.

[68]  R. Heyman,et al.  Low‐dose methotrexate treatment for moderate‐to‐severe atopic dermatitis in adults , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[69]  S. Holland,et al.  Combined immunodeficiency associated with DOCK8 mutations. , 2009, The New England journal of medicine.

[70]  H. Williams,et al.  Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. , 2009, The Journal of allergy and clinical immunology.

[71]  K. Barnes,et al.  Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. , 2009, The Journal of allergy and clinical immunology.

[72]  P. Schlievert,et al.  Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle‐controlled trial , 2009, The British journal of dermatology.

[73]  Aziz Sheikh,et al.  Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis , 2009, BMJ : British Medical Journal.

[74]  M. Kopp,et al.  Probiotics cannot be generally recommended for primary prevention of atopic dermatitis. , 2009, The Journal of allergy and clinical immunology.

[75]  H. Cordell,et al.  Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. , 2009, The Journal of allergy and clinical immunology.

[76]  Lisa C. Zaba,et al.  IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.

[77]  A. Rademaker,et al.  Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity , 2009, Pediatrics.

[78]  A. Shiohama,et al.  A homozygous frameshift mutation in the murine filaggrin gene facilitates enhanced percutaneous allergen priming , 2009, Nature Genetics.

[79]  T. Holland-Letz,et al.  Medium‐dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study , 2009, The British journal of dermatology.

[80]  G. Stingl,et al.  Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. , 2008, The Journal of allergy and clinical immunology.

[81]  A. Stolfi,et al.  Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[82]  J. Leonardi-Bee,et al.  Probiotics for treating eczema. , 2008, The Cochrane database of systematic reviews.

[83]  R. Gallo,et al.  Administration of oral vitamin D induces cathelicidin production in atopic individuals. , 2008, The Journal of allergy and clinical immunology.

[84]  R. Katz,et al.  Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. , 2008, Allergy and asthma proceedings.

[85]  R. Gallo,et al.  Antimicrobial peptides and the skin immune defense system. , 2008, The Journal of allergy and clinical immunology.

[86]  H. Cordell,et al.  Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema. , 2008, The Journal of investigative dermatology.

[87]  A. Paller,et al.  MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. , 2008, The Journal of pediatrics.

[88]  Donald Y M Leung,et al.  A multidisciplinary approach to evaluation and treatment of atopic dermatitis. , 2008, Seminars in cutaneous medicine and surgery.

[89]  A. Woodcock,et al.  Gene-Environment Interaction in the Onset of Eczema in Infancy: Filaggrin Loss-of-Function Mutations Enhanced by Neonatal Cat Exposure , 2008, PLoS medicine.

[90]  W. Silny,et al.  Contact allergy to glucocorticosteroids in patients with chronic venous leg ulcers, atopic dermatitis and contact allergy. , 2008, Acta dermatovenerologica Croatica : ADC.

[91]  M. Pembrey,et al.  The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. , 2008, The Journal of allergy and clinical immunology.

[92]  A. Heinzmann,et al.  Randomized, Double-Blind, Placebo-Controlled Trial of Probiotics for Primary Prevention: No Clinical Effects of Lactobacillus GG Supplementation , 2008, Pediatrics.

[93]  M. Boguniewicz,et al.  Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. , 2008, Clinical immunology.

[94]  Ds Kim,et al.  The effect of wet‐wrap dressing on epidermal barrier in patients with atopic dermatitis , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[95]  J. Ring,et al.  Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. , 2007, The Journal of allergy and clinical immunology.

[96]  Bodo Grimbacher,et al.  STAT3 mutations in the hyper-IgE syndrome. , 2007, The New England journal of medicine.

[97]  H. Ochs,et al.  Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. , 2007, The Journal of allergy and clinical immunology.

[98]  S. Spector,et al.  Allergen immunotherapy: a practice parameter third update. , 2007, The Journal of allergy and clinical immunology.

[99]  T. Bieber,et al.  Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[100]  H. Jacobe,et al.  Phototherapy in the management of atopic dermatitis: a systematic review , 2007, Photodermatology, photoimmunology & photomedicine.

[101]  E. Warshaw,et al.  Contact dermatitis of the hands: cross-sectional analyses of North American Contact Dermatitis Group Data, 1994-2004. , 2007, Journal of the American Academy of Dermatology.

[102]  K. Barnes,et al.  Cytokine modulation of atopic dermatitis filaggrin skin expression. , 2007, The Journal of allergy and clinical immunology.

[103]  S. Orlow,et al.  Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients , 2007, The British journal of dermatology.

[104]  G. Canonica,et al.  Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. , 2007, The Journal of allergy and clinical immunology.

[105]  E. Warshaw,et al.  Common Contact Allergens Associated with Eyelid Dermatitis: Data from the North American Contact Dermatitis Group 2003‐2004 Study Period , 2007, Dermatitis : contact, atopic, occupational, drug.

[106]  C. Paul,et al.  Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. , 2007, The Journal of investigative dermatology.

[107]  N. Reynolds,et al.  An open‐label, dose‐ranging study of methotrexate for moderate‐to‐severe adult atopic eczema , 2007, The British journal of dermatology.

[108]  N. Novak,et al.  Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? , 2006, The Journal of allergy and clinical immunology.

[109]  P. Schmid‐Grendelmeier,et al.  Sensitization to the yeast Malassezia sympodialis is specific for extrinsic and intrinsic atopic eczema. , 2006, The Journal of investigative dermatology.

[110]  T. H. Clayton,et al.  The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy , 2006, Clinical and experimental dermatology.

[111]  S. Silva,et al.  Influence of narrow‐band UVB phototherapy on cutaneous microbiota of children with atopic dermatitis , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[112]  B. Niggemann,et al.  The atopy patch test in the diagnostic workup of suspected food-related symptoms in children. , 2006, The Journal of allergy and clinical immunology.

[113]  A. Bosio,et al.  Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. , 2006, The Journal of allergy and clinical immunology.

[114]  M. Steinhoff,et al.  Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. , 2006, The Journal of investigative dermatology.

[115]  A. Muraro,et al.  Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. , 2006, The Journal of allergy and clinical immunology.

[116]  Paul G. Vigo,et al.  Efficacy of anti-IgE therapy in patients with atopic dermatitis. , 2006, Journal of the American Academy of Dermatology.

[117]  K. Kelsay.  Management of sleep disturbance associated with atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[118]  Torsten Zuberbier,et al.  Patient perspectives on the management of atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[119]  T. Agner,et al.  Development of atopic dermatitis during the first 3 years of life: the Copenhagen prospective study on asthma in childhood cohort study in high-risk children. , 2006, Archives of dermatology.

[120]  M. Flaig,et al.  Cathelicidin deficiency predisposes to eczema herpeticum. , 2006, The Journal of allergy and clinical immunology.

[121]  Colin N A Palmer,et al.  Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis , 2006, Nature Genetics.

[122]  F. Bérard,et al.  Methotrexate for the treatment of adult atopic dermatitis. , 2006, European journal of dermatology : EJD.

[123]  L. Ou,et al.  Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes. , 2006, The Journal of allergy and clinical immunology.

[124]  M. Steinhoff,et al.  IL-31: a new link between T cells and pruritus in atopic skin inflammation. , 2006, The Journal of allergy and clinical immunology.

[125]  M. Worm,et al.  Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi‐centre, randomized, dose–response study , 2006, Allergy.

[126]  B. Harder,et al.  IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[127]  M. Cork,et al.  Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years , 2006, Pediatrics.

[128]  J. Coste,et al.  The first images of atopic dermatitis: an attempt at retrospective diagnosis in dermatology. , 2005, Journal of the American Academy of Dermatology.

[129]  S. Ziegler,et al.  Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin , 2005, The Journal of experimental medicine.

[130]  S. Hsu,et al.  Failure of omalizumab for treatment of severe adult atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[131]  E. Jaracz,et al.  Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[132]  M. Boguniewicz,et al.  Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. , 2005, The Journal of allergy and clinical immunology.

[133]  M. Yazdanbakhsh,et al.  Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. , 2005, The Journal of allergy and clinical immunology.

[134]  P. Schmid‐Grendelmeier,et al.  IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. , 2005, The Journal of allergy and clinical immunology.

[135]  S. Prescott,et al.  Effects of probiotics on atopic dermatitis: a randomised controlled trial , 2005, Archives of Disease in Childhood.

[136]  J. Ortonne,et al.  Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. , 2005, Journal of the American Academy of Dermatology.

[137]  T. Tezuka,et al.  Prevalence of atopic dermatitis in Japanese elementary schoolchildren , 2005, The British journal of dermatology.

[138]  B. Niggemann,et al.  The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. , 2004, The Journal of allergy and clinical immunology.

[139]  M. Boguniewicz,et al.  Current management of atopic dermatitis and interruption of the atopic march. , 2003, The Journal of allergy and clinical immunology.

[140]  I. Reischl,et al.  Surface expression of Fc epsilon RI on Langerhans' cells of clinically uninvolved skin is associated with disease activity in atopic dermatitis, allergic asthma, and rhinitis. , 2003, The Journal of allergy and clinical immunology.

[141]  S. Salminen,et al.  Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial , 2003, The Lancet.

[142]  V. Ho,et al.  Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. , 2003, The Journal of pediatrics.

[143]  Hugh A Sampson,et al.  9. Food allergy. , 2003, The Journal of allergy and clinical immunology.

[144]  K. Michaelsen,et al.  Effect of probiotic lactobacillus strains in children with atopic dermatitis , 2003, The Journal of allergy and clinical immunology.

[145]  Tomas Ganz,et al.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis. , 2002, The New England journal of medicine.

[146]  J. Ortonne,et al.  Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. , 2002, The Journal of allergy and clinical immunology.

[147]  T. Diepgen.  Long‐term treatment with cetirizine of infants with atopic dermatitis: A multi‐country, double‐blind, randomized, placebo‐controlled trial (the ETAC™ trial) over 18 months , 2002 .

[148]  P. Elias,et al.  Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. , 2002, Journal of the American Academy of Dermatology.

[149]  U. Wahn,et al.  Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. , 2002, Pediatrics.

[150]  S. Jolles.  A review of high‐dose intravenous immunoglobulin treatment for atopic dermatitis , 2002, Clinical and experimental dermatology.

[151]  M. Boguniewicz,et al.  Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. , 2001, The Journal of allergy and clinical immunology.

[152]  M. Boguniewicz,et al.  Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. , 2001, The Journal of allergy and clinical immunology.

[153]  U. Wahn,et al.  Low‐dose cyclosporin A microemulsion in children with severe atopic dermatitis: Clinical and immunological effects , 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[154]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.

[155]  A. Scheynius,et al.  Effectiveness of occlusive bedding in the treatment of atopic dermatitis – a placebo‐controlled trial of 12 months' duration , 2001, Allergy.

[156]  E. Knol,et al.  Differences in antigen-specific T-cell responses between infants with atopic dermatitis with and without cow's milk allergy: relevance of TH2 cytokines. , 2000, The Journal of allergy and clinical immunology.

[157]  A. Wolkerstorfer,et al.  Efficacy and safety of wet‐wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution , 2000, The British journal of dermatology.

[158]  C. Bruijnzeel-Koomen,et al.  Modulation of the atopy patch test reaction by topical corticosteroids and tar. , 2000, The Journal of allergy and clinical immunology.

[159]  C. Berge,et al.  The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. , 2000, Cutis.

[160]  J. Istvan,et al.  The prevalence of atopic dermatitis in Oregon schoolchildren. , 2000, Journal of the American Academy of Dermatology.

[161]  G. Imokawa,et al.  High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. , 2000, The Journal of investigative dermatology.

[162]  T. Shiohara,et al.  Increased circulating skin‐homing cutaneous lymphocyte‐associated antigen (CLA)+ type 2 cytokine‐producing cells, and decreased CLA+ type 1 cytokine‐producing cells in atopic dermatitis , 2000, The British journal of dermatology.

[163]  A. Goossens,et al.  Contact allergy to corticosteroids , 2000, Allergy.

[164]  E. Chan,et al.  Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. , 2000, The Journal of allergy and clinical immunology.

[165]  F. McGlone,et al.  Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study , 2000, The British journal of dermatology.

[166]  H. Williams,et al.  Topical corticosteroid phobia in patients with atopic eczema , 2000, The British journal of dermatology.

[167]  E. Knol,et al.  Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. , 2000, The Journal of allergy and clinical immunology.

[168]  S. Muro,et al.  Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. , 2000, The Journal of allergy and clinical immunology.

[169]  G. Chrousos,et al.  Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. , 2000, The Journal of allergy and clinical immunology.

[170]  U. Wahn,et al.  Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. , 2000, The Journal of allergy and clinical immunology.

[171]  L. Skov,et al.  Application of Staphylococcal enterotoxin B on normal and atopic skin induces up-regulation of T cells by a superantigen-mediated mechanism. , 2000, The Journal of allergy and clinical immunology.

[172]  D. Gustafsson,et al.  Development of allergies and asthma in infants and young children with atopic dermatitis – a prospective follow‐up to 7 years of age , 2000, Allergy.

[173]  R. Valenta,et al.  Autoallergy: a pathogenetic factor in atopic dermatitis? , 2000, Current problems in dermatology.

[174]  J. Ring,et al.  Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. , 2000, Journal of the American Academy of Dermatology.

[175]  A. Finlay,et al.  Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy , 2000, The British journal of dermatology.

[176]  M. Wjst,et al.  Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. , 1999, The Journal of allergy and clinical immunology.

[177]  C. Akdis,et al.  T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. , 1999, The Journal of investigative dermatology.

[178]  S. Beissert,et al.  Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. , 1999, Journal of the American Academy of Dermatology.

[179]  M. Rapaport,et al.  Eyelid dermatitis to red face syndrome to cure: Clinical experience in 100 cases , 1999 .

[180]  H. Sampson,et al.  Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. , 1999, The Journal of allergy and clinical immunology.

[181]  C. Koblenzer.  Itching and the atopic skin. , 1999, The Journal of allergy and clinical immunology.

[182]  M. Lebwohl,et al.  A comparison of once‐daily application of mometasone furoate 0.1% cream compared with twice‐daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone , 1999, International journal of dermatology.

[183]  H. Saito,et al.  Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis. , 1999, The Journal of allergy and clinical immunology.

[184]  E. Minshall,et al.  Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonasthmatic individuals. , 1999, The Journal of allergy and clinical immunology.

[185]  L. Picker,et al.  Evidence for superantigen involvement in skin homing of T cells in atopic dermatitis. , 1999, The Journal of investigative dermatology.

[186]  P. Schlievert,et al.  Staphylococcal toxins augment specific IgE responses by atopic patients exposed to allergen. , 1999, The Journal of investigative dermatology.

[187]  R. Valenta,et al.  Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. , 1998, The Journal of investigative dermatology.

[188]  Q. Hamid,et al.  Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. , 1998, The Journal of allergy and clinical immunology.

[189]  Takami Yoshida,et al.  Unique profile of IL-4 and IFN-gamma production by peripheral blood mononuclear cells in infants with atopic dermatitis. , 1998, The Journal of allergy and clinical immunology.

[190]  Bergmann,et al.  Atopic dermatitis in early infancy predicts allergic airway disease at 5 years , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[191]  A. Wolkerstorfer,et al.  Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. , 1998, Journal of the American Academy of Dermatology.

[192]  David B. Speights,et al.  High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[193]  H. Tagami,et al.  A twenty-four-hour occlusive exposure to 1% sodium lauryl sulfate induces a unique histopathologic inflammatory response in the xerotic skin of atopic dermatitis patients. , 1998, Acta dermato-venereologica.

[194]  T. Hamilton,et al.  Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. , 1998, Archives of dermatology.

[195]  M. Boguniewicz,et al.  Atopic dermatitis: a question of balance. , 1998, Archives of dermatology.

[196]  K. Tanaka,et al.  Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. , 1998, Acta dermato-venereologica.

[197]  J. Leyden,et al.  S. aureus isolation from the lesions, the hands, and the anterior nares of patients with atopic dermatitis. , 1998 .

[198]  Richard Beasley,et al.  Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC , 1998, The Lancet.

[199]  R. Geha,et al.  Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. , 1998, The Journal of clinical investigation.

[200]  T. Luger,et al.  High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. , 1998, Journal of the American Academy of Dermatology.

[201]  D. Zurakowski,et al.  Long-Term Therapy with Recombinant Interferon-Gamma (rIFN-γ) for Atopic Dermatitis , 1998 .

[202]  U. Wahn,et al.  A human-SCID mouse model for allergic immune response bacterial superantigen enhances skin inflammation and suppresses IgE production. , 1998, The Journal of investigative dermatology.

[203]  A. Finlay,et al.  A practical guide to topical therapy in children , 1998, The British journal of dermatology.

[204]  C. Bruijnzeel-Koomen,et al.  T-cell reactivity for a peanut-derived epitope in the skin of a young infant with atopic dermatitis. , 1998, The Journal of allergy and clinical immunology.

[205]  A. Lucky,et al.  Use of an Emollient As a Steroid‐Sparing Agent in the Treatment of Mild to Moderate Atopic Dermatitis in Children , 1997, Pediatric dermatology.

[206]  D. Umetsu,et al.  Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. , 1997, Journal of immunology.

[207]  L. Koenderman,et al.  Bronchial and skin reactivity in asthmatic patients with and without atopic dermatitis. , 1997, The European respiratory journal.

[208]  D. Moneret-vautrin,et al.  Transfer of atopy following bone marrow transplantation. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[209]  J. English,et al.  Long‐term efficacy and safety of cyclosporin in severe adult atopic dermatitis , 1997, The British journal of dermatology.

[210]  E. Minshall,et al.  In vivo expression of IL-12 and IL-13 in atopic dermatitis. , 1996, The Journal of allergy and clinical immunology.

[211]  R. Tupker,et al.  Induction of atopic dermatitis by inhalation of house dust mite. , 1996, The Journal of allergy and clinical immunology.

[212]  Å. Svensson,et al.  The occurrence of atopic dermatitis in north Europe: an international questionnaire study. , 1996, Journal of the American Academy of Dermatology.

[213]  C. Bruijnzeel-Koomen,et al.  Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. , 1996, The Journal of allergy and clinical immunology.

[214]  I. Strickland,et al.  Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis , 1996, The Lancet.

[215]  N. Kondo,et al.  Prevalence of and risk factors for allergic diseases: comparison of two cities in Japan. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[216]  T. Bieber,et al.  Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc epsilon RI. , 1995, Journal of immunology.

[217]  R. Zeiger,et al.  The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. , 1995, The Journal of allergy and clinical immunology.

[218]  L. Picker,et al.  Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen , 1995, The Journal of experimental medicine.

[219]  L. Picker,et al.  Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. , 1995, The Journal of clinical investigation.

[220]  M. Sinisalo,et al.  Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy , 1995, The British journal of dermatology.

[221]  F. Storrs,et al.  Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. , 1994, Archives of dermatology.

[222]  A. Sober,et al.  Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. , 1994, Journal of the American Academy of Dermatology.

[223]  J. Stalder,et al.  Local steroid therapy and bacterial skin flora in atopic dermatitis , 1994, The British journal of dermatology.

[224]  Q. Hamid,et al.  Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. , 1994, The Journal of clinical investigation.

[225]  B. Wüthrich,et al.  Lokalisationen, Manifestationstypen sowie Mikromanifestationen der atopischen Dermatitis bei jungen Erwachsenen , 1994, Der Hautarzt.

[226]  W. Vloten,et al.  Cyclosporin in atopic dermatitis: a multicentre placebo‐controlled study , 1994, The British journal of dermatology.

[227]  D. Strachan,et al.  Childhood eczema: disease of the advantaged? , 1994, BMJ.

[228]  P. Norris,et al.  Oral psoralen photochemotherapy in severe childhood atopic eczema: an update , 1993, The British journal of dermatology.

[229]  H. Sampson,et al.  Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. , 1993, The Journal of clinical investigation.

[230]  J. Saurat,et al.  Th2 cells mediate IL-4-dependent local tissue inflammation. , 1993, Journal of immunology.

[231]  N. Holm,et al.  Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. , 1993, Journal of the American Academy of Dermatology.

[232]  S. Walker,et al.  Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. , 1993, The Journal of clinical investigation.

[233]  O. Tammela,et al.  Ten‐year prognosis for generalized infantile eczema , 1992, Acta paediatrica.

[234]  H. Williams,et al.  Is the prevalence of atopic dermatitis increasing? , 1992, Clinical and experimental dermatology.

[235]  T. Sullivan,et al.  Endogenous cortisol regulates immunoglobulin E-dependent late phase reactions. , 1992, The Journal of clinical investigation.

[236]  H. Sampson,et al.  Genetic and environmental factors affecting the development of atopy through age 4 in children of atopic parents: a prospective randomized study of food allergen avoidance , 1992 .

[237]  C. Bruijnzeel-Koomen,et al.  Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. , 1992, The Journal of allergy and clinical immunology.

[238]  M. Glover,et al.  A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[239]  J. Leyden,et al.  Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid. , 1992, Journal of the American Academy of Dermatology.

[240]  J. Krutmann,et al.  High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. , 1992, Journal of the American Academy of Dermatology.

[241]  A. Azon,et al.  Clinical and non-invasive evaluation of 12% ammonium lactate emulsion for the treatment of dry skin in atopic and non-atopic subjects. , 1992, Acta dermato-venereologica.

[242]  J. Bos,et al.  High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. , 1991, The Journal of investigative dermatology.

[243]  K. Lammintausta,et al.  Prognosis of Atopic Dermatitis , 1991, International journal of dermatology.

[244]  A. Y. Finlay,et al.  Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis , 1991, The Lancet.

[245]  M Kawashima,et al.  Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? , 1991, The Journal of investigative dermatology.

[246]  R. Geha,et al.  Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. , 1990, The American journal of medicine.

[247]  C. Bruijnzeel-Koomen,et al.  Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE. , 1990, Immunology.

[248]  R. Geha,et al.  IL-4 inhibits the synthesis of IFN-gamma and induces the synthesis of IgE in human mixed lymphocyte cultures. , 1990, Journal of immunology.

[249]  A. Adinoff,et al.  The relationship between positive aeroallergen patch test reactions and aeroallergen exacerbations of atopic dermatitis. , 1989, Clinical immunology and immunopathology.

[250]  H. Sampson,et al.  Spontaneous release of histamine from basophils and histamine-releasing factor in patients with atopic dermatitis and food hypersensitivity. , 1989, The New England journal of medicine.

[251]  H. Sampson,et al.  Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. , 1985, The Journal of pediatrics.

[252]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[253]  J. Leyden,et al.  The case for steroid—antibiotic combinations , 1977, The British journal of dermatology.

[254]  C. May,et al.  Objective clinical and laboratory studies of immediate hypersensitivity reactions to foods in asthmatic children. , 1976, The Journal of allergy and clinical immunology.

[255]  J. Leyden,et al.  Staphylococcus aureus in the lesions of atopic dermatitis , 1974, The British journal of dermatology.

[256]  L. Tuft.  Importance of inhalant allergens in atopic dermatitis. , 1949, The Journal of investigative dermatology.

[257]  M. B. Sulzberger,et al.  EVOLUTION OF ATOPIC DERMATITIS , 1935 .

[258]  E. Guttman‐Yassky,et al.  New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[259]  Donald Y M Leung,et al.  Amendment history : Erratum ( April 2004 ) New insights into atopic dermatitis , 2018 .

[260]  J. Silverberg,et al.  Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[261]  S. Spector,et al.  Practice parameter Atopic dermatitis : A practice parameter update 2012 , 2013 .

[262]  Carolyn J. Broccardo,et al.  Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. , 2011, The Journal of allergy and clinical immunology.

[263]  E. Simpson,et al.  Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. , 2011, The Journal of investigative dermatology.

[264]  P. Schlievert,et al.  Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. , 2010, The Journal of allergy and clinical immunology.

[265]  Donald Y M Leung,et al.  Recent insights into atopic dermatitis and implications for management of infectious complications. , 2010, The Journal of allergy and clinical immunology.

[266]  K. Barnes.  An update on the genetics of atopic dermatitis: scratching the surface in 2009. , 2010, The Journal of allergy and clinical immunology.

[267]  M. D. de Bruin‐Weller,et al.  Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. , 2009, Journal of the American Academy of Dermatology.

[268]  D. Margolis,et al.  The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. , 2008, Journal of the American Academy of Dermatology.

[269]  L. Bielory,et al.  Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. , 2008, The Journal of allergy and clinical immunology.

[270]  H. Simon,et al.  Anti-CD20 (rituximab) treatment improves atopic eczema. , 2008, The Journal of allergy and clinical immunology.

[271]  이주희,et al.  The effect of wet-wrap dressing on epidermal barrier in patients with atopic dermatitis , 2007 .

[272]  D. Cohen,et al.  Treatment of recalcitrant atopic dermatitis with omalizumab. , 2006, Journal of the American Academy of Dermatology.

[273]  B. Wüthrich.  Natural History of Atopic Eczema , 2006 .

[274]  S. Jolles,et al.  Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. , 1999, Journal of the American Academy of Dermatology.

[275]  U. Wahn,et al.  Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. , 1999, The Journal of allergy and clinical immunology.

[276]  S. Szefler,et al.  Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. , 1997, American journal of respiratory and critical care medicine.

[277]  L. Skov,et al.  Staphylococcal enterotoxin B applied on intact normal and intact atopic skin induces dermatitis. , 1996, Archives of dermatology.

[278]  W. Shelley,et al.  Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. , 1996, Journal of the American Academy of Dermatology.

[279]  D. Gawkrodger,et al.  The prevalence of childhood atopic eczema in a general population. , 1994, Journal of the American Academy of Dermatology.

[280]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .

[281]  S. Spector,et al.  Practice Parameter Contact Dermatitis : A Practice Parameter e Update 2015 , 2022 .